title: Spontaneous regression of low-grade cervical intraepithelial lesions is positively improved by topical bovine colostrum preparations (GINEDIE®). A multicentre, observational, italian pilot study.
abstract: OBJECTIVE
  Human papillomavirus (HPV) is the causal agent of cervical cancer. The great majority of abnormal Pap test results - almost 90% - is referrable to either atypical squamous intraepithelial lesion or CIN1. For these lesions, worldwide agreement exists concerning the high rate - ranging from 40% to 70% - of spontaneous regression over a period of 1-5 years. Host's immune response is a key point influencing the natural history of these conditions. Bovine colostrum is a natural agent positively promoting several immune activities against bacterial and viral agents. The aim of this report was to evaluate the potential positive effect of bovine colostrum-containing vaginal tablets administered to CIN1 diagnosed patients in a prospective trial in regards to spontaneous regression rate.
  
  
  METHODS
  A series of 256 consecutive patients with histologically proven CIN1 recruited in a multicentre, observational, Italian study. Patients have been enrolled in a 24-weeks protocol of treatment and re-tested at the end of the study. Rates of regression have been recorded.
  
  
  RESULTS
  Overall regression rate to a negative histology at the end of the 6 month follow up was 75.5%.
  
  
  CONCLUSIONS
  Regression to normal histology was observed in a very high rate of cases in a very short period compared to the natural history of these lesions. CIN1 patients could benefit from bovine colostrum topical administration in terms of significantly shortening the regression time.
authors.affiliation: Department of Obstetrics and Gynecology, Vita Salute San Raffaele University School of Medicine, Milan, Italy. massimo.origoni@hsr.it  
authors.forename: C
authors.initials: C
authors.lastname: Stefani
authors.forename: C A
authors.initials: CA
authors.lastname: Liverani
authors.forename: V
authors.initials: V
authors.lastname: Bianco
authors.forename: C
authors.initials: C
authors.lastname: Penna
authors.forename: T
authors.initials: T
authors.lastname: Guarnieri
authors.forename: C
authors.initials: C
authors.lastname: Comparetto
authors.forename: E
authors.initials: E
authors.lastname: Monti
authors.forename: I
authors.initials: I
authors.lastname: Valente
authors.forename: A L
authors.initials: AL
authors.lastname: Pieralli
authors.forename: C
authors.initials: C
authors.lastname: Fiaschi
authors.forename: M
authors.initials: M
authors.lastname: Origoni
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000818:Animals; D001685:Biological Factors / Q000008:administration & dosage*; D002417:Cattle; D003126:Colostrum; D005260:Female; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008875:Middle Aged; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000175:diagnosis / Q000628:therapy*; D010865:Pilot Projects; D011247:Pregnancy; D011446:Prospective Studies; D012075:Remission, Spontaneous; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000628:therapy*; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000628:therapy*
chemical_list: D001685:Biological Factors